Remove Biopharma Remove Healthcare Remove Pharmaceutical manufacturing
article thumbnail

AmerisourceBergen agrees to acquire PharmaLex for $1.29bn

Pharmaceutical Technology

The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product. On closing of the deal, the results of PharmaLex will be included as a component within the International Healthcare Solutions sector of AmerisourceBergen.

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

In particular, for the pharmaceutical industry, these talent shortages bring about a host of difficult challenges. This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Training and development. Raising the profile.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines.

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.

article thumbnail

Sustainability Measures Enable Long-Term Growth in Pharma Manufacturing

PM360

In late 2023, Deloitte found that over half of 105 surveyed global biopharma leaders were committed to reducing environmental impact and advancing sustainability by minimizing water use, sourcing sustainable materials, and overhauling supply chains.

article thumbnail

CMS enters drug price negotiation arena in sea change for industry

Clarivate

In announcing the results of price negotiations between the Centers for Medicare & Medicaid Services (CMS) and pharmaceutical manufacturers, the federal government has demonstrated that it can replicate private payers’ ability to reduce the net price of treatment while focusing on the clinical benefit of a treatment versus therapeutic alternatives (..)